Firm

Selin Sinem Erciyas of Gün + Partners suggests that intellectual property waivers and compulsory licensing are not the answer in developing and accessing vaccines, and explains why governments should be focused on R&D

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees

Xiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy

CAS explains the five high-risk areas of IP for R&D organisations and identifies how companies can protect their innovations and safeguard their growth potential

CAS shares how patent offices around the world are adopting AI, and explains the benefits of clean data, multiple algorithms, and leveraging human expertise alongside technology

The CAS IP Research Team analyse how organisations are applying IP insights to accelerate scientific breakthroughs and identify potential risks to commercialisation